SOLICITATION NOTICE
66 -- Laboratory Equipment - Luminex 200
- Notice Date
- 8/1/2016
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2016-Q-00994
- Archive Date
- 8/30/2016
- Point of Contact
- matthew ellington, Phone: 7704880073
- E-Mail Address
-
mce8@cdc.gov
(mce8@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Center for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases intends to award a sole source purchase order to R&D Systems 614 McKinley Place NE Minneapolis, MN 55413; to obtain a LX200-XPON3 LX-200 with xPONENT 3.11 w/software. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c) (1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing with a size standard in number of employees 500. The period of performance is (60) days. The purpose of this procurement of the Luminex 200 (LX200-XPON3 LX-200) instrument is a bead-based technology that is unlike other pieces of equipment that can perform similar assays. The advantages of this technology is that it is flexible, which will allow us to perform several different studies with this instrument that the agency could not do on other instruments that use a different technology. This system also allows for multiplexing of up to 100 analytes with a low sample volume required (25 μl). This system has the largest portfolio of multiplex assays for biomarker screening and protein analysis and can perform nucleic acid assays, receptor-ligand assays, immunoassays, and enzymatic assays. R&D Systems is the only responsible source capable of meeting all of the Government's requirement because they are the only manufacturers of the Luminex 200 (LX200-XPON3 LX-200). Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit capabilities statements to the Contracting Officer within 15 days from the posting date of this notice. The Government will review all capabilities statements submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement. The capability statements shall be submitted electronically via e-mail to the Contracting Specialist Matthew Ellington at mce8@cdc.gov on or before 2:00 pm (1400) EASTERN STANDARD TIME on August 15, 2016. All email responses to this notice must identify the RFQ#2016-Q-00994, in the subject line of the email. FAXED OR MAILED RESPONSES AND/OR QUESTIONS WILL NOT BE CONSIDERED.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2016-Q-00994/listing.html)
- Place of Performance
- Address: 2920 Brandywine Rd, Atlanta, Georgia, 30341, United States
- Zip Code: 30341
- Zip Code: 30341
- Record
- SN04202808-W 20160803/160801234303-9a20bea3ad33d193145fd8713c18be79 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |